Loading clinical trials...
Loading clinical trials...
Phase I/IIa, First-in-human, Open-label, Dose Escalation Trial With Expansion Cohorts to Evaluate Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BNT151 as a Monotherapy and in Combination With Other Anti-cancer Agents in Patients With Solid Tumors
Conditions
Interventions
BNT151
Locations
6
United States
Yale Cancer Center
New Haven, Connecticut, United States
Sarah Cannon Research Institute at Tennessee Oncology
Nashville, Tennessee, United States
University of Texas MD Anderson Cancer Center
Houston, Texas, United States
NEXT Oncology
San Antonio, Texas, United States
Vall d´Hebron Institute of Oncology (VHIO)
Barcelona, Spain
START Madrid - HM CIOCC
Madrid, Spain
Start Date
January 26, 2021
Primary Completion Date
May 28, 2024
Completion Date
May 28, 2024
Last Updated
July 2, 2025
NCT06144671
NCT06132828
NCT04570423
NCT06926283
NCT07489378
NCT07177937
Lead Sponsor
BioNTech SE
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions